Amavita Research vs. Cleveland Clinic Florida: which clinical trial site fits your study?

Amavita Research is a clinical trial site and PET imaging trial partner in North Miami Beach, anchored by a dedicated cardiovascular research site. Every active study is cardiovascular, the senior PI is U.S. TAVR pioneer Dr. William W. O'Neill (National PI on Edwards PARTNER, Protect II, and Protect IV), and the affiliated Advanced Cardiovascular of Miami ASC supports interventional procedures on site. Site processes are IAOCR GCSA-certified, valid through February 28, 2027.

Cleveland Clinic Florida in Weston houses the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute, and the system runs C5Research - the Cleveland Clinic Coordinating Center for Clinical Research - an academic research organization that designs and coordinates Phase I-IV multicenter cardiovascular trials, with endpoint adjudication and imaging core capabilities. For sponsors that want academic leadership embedded in trial design and multicenter coordination, that infrastructure is genuinely distinctive.

The trade-off is role in the program. An academic coordinating center leads science: protocol design, endpoint committees, and publication-grade governance across many sites. An independent executing site leads enrollment: startup speed, patient flow, and single-site accountability for the cohort in front of it.

Amavita's value is executional. An anonymized 41-day contract-to-first-patient-in metric, a single BD owner (Nereisy Alonso, COO) with same-business-day response, a Miami patient population sized for FDA Diversity Action Plan targets, and cardiac PET and radiopharmaceutical trial capability for the growing CV imaging-tracer pipeline.

Many sponsor programs use both models: the academic center for scientific leadership and coordination, and an independent specialist site like Amavita as a high-enrolling South Florida anchor. The right question is which role your protocol needs filled in Miami.